MARKET

CYTO

CYTO

Altamira Therapeutics Ltd
NASDAQ
5.53
+0.19
+3.56%
Closed 16:00 12/08 EST
OPEN
5.30
PREV CLOSE
5.34
HIGH
5.56
LOW
5.28
VOLUME
13.21K
TURNOVER
29.90K
52 WEEK HIGH
46.00
52 WEEK LOW
4.600
MARKET CAP
6.08M
P/E (TTM)
-0.2152
1D
5D
1M
3M
1Y
5Y
Altamira Therapeutics Reaches Midpoint For Enrollment In Clinical Trial With Bentrio In Seasonal Allergic Rhinitis In Australia
Benzinga · 6d ago
Altamira Therapeutics Achieves Midpoint Enrollment in Bentrio Trial for Allergic Rhinitis
Altamira Therapeutics Achieves Midpoint Enrollment in Bentrio Trial for Allergic Rhinitis
MT Newswires · 12/02 11:27
BRIEF-Altamira Therapeutics Provides Business Update And First Half 2022 Financial Results
Reuters · 11/30 14:41
Altamira Therapeutics Announces Launch Of Bentrio In Hong Kong By Its Partner Nuance Pharma
Benzinga · 11/30 13:08
Altamira Therapeutics Partner Launches Bentrio Nasal Spray in Hong Kong
Altamira Therapeutics Partner Launches Bentrio Nasal Spray in Hong Kong
MT Newswires · 11/30 10:42
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability
Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the presentation of animal data generated by an atherosclerosis research group at ...
ACCESSWIRE · 11/22 13:47
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
Hamilton, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- • TIDES Europe Event will be held on November 16-18, 2022, in Vienna, Austria• Company Chief Development Officer, Covadonga Pañeda, Ph.D., to present on the advantages of Altamira’s OligoPhoreTM / SemaPh...
GlobeNewswire · 11/10 13:47
Altamira Therapeutics regains listing compliance with Nasdaq
Seekingalpha · 11/09 14:37
More
About CYTO
Auris Medical Holding AG is a Switzerland-based biotechnologyompany focused on developing and commercializing therapeutics and medical devices for neurotology, rhinology and allergy and central nervous system (CNS) disorders.The Company is active in active in three areas such as: the development of oligonucleotides for extrahepatic therapeutic targets - OligoPhore platform; nasal sprays for protection against airborne viruses and allergens Bentrio or the treatment of vertigo AM-125 ; he development of therapeutics for intratympanic treatment of tinnitus Keyzilen or hearing loss Sonsuvi .

Webull offers kinds of Altamira Therapeutics Ltd stock information, including NASDAQ:CYTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTO stock methods without spending real money on the virtual paper trading platform.